Physician profile
Afriyie Makel Gray
NPI 1477842904
$11,893.39
in general payments reported to CMS, 2019-2025
17 companies · $2,601 in 2025
The $2,601 reported for 2025 was more than what 96% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $123 · 2024: $9,170 · 2025: $2,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,075 · Food and Beverage: $4,986 · Travel and Lodging: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,075.00 |
| Food and Beverage | $4,986.24 |
| Travel and Lodging | $1,832.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $7,276.03 | 2024-2025 | Kisunla, Mounjaro, Zepbound |
| Amgen INC. | $1,493.49 | 2024-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $785.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $598.68 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $419.84 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $279.92 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $225.10 | 2024-2025 | Rexulti |
| Eisai INC. | $142.49 | 2024-2025 | |
| Exact Sciences Corporation | $131.57 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.95 | 2024-2025 | Caplyta |
| Esperion Therapeutics, INC. | $106.75 | 2024-2025 | Nexletol |
| Abbvie INC. | $101.61 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.95 | 2024-2025 | |
| Hologic Sales and Service, LLC | $39.05 | 2023 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.31 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $26.33 | 2024 | Gemtesa |
| Dexcom, INC. | $18.02 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afriyie Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.